Telix Pharmaceuticals Limited (ASX: TLX) - Share Price
Current share price for TLX : $15.730 1.17 (8.04%)+
Telix Pharmaceuticals Limited (TLX), an ASX-listed company, is a global biopharmaceutical company engaged in the development and commercialization of targeted therapeutic and diagnostic radiopharmaceuticals, along with supporting medical technologies. Headquartered in Melbourne, Australia, Telix maintains strategic international operations across the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan.
TLX General Information +
| ASX Code | TLX |
| Website | N/A |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 5,338 |
| TLX Share Price | $15.730 |
| Day High | $16.060 |
| Day Low | $14.670 |
| Last Close | $14.560 |
| TLX Share Price Movement | $1.17 ( 8.04% ) |
Prices as at 16:40, 24 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Telix Pharmaceuticals Limited (TLX) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Telix Pharmaceuticals Limited (TLX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Telix Pharmaceuticals Limited (TLX) price-sensitive announcements
TLX - Convertible Bond Cleansing Notice
Telix Pharmaceuticals Limited has successfully priced an upsized US$600 million convertibl
Telix Pharmaceuticals Limited (TLX)
20 Apr 2026 | 4:47 PM
20 Apr 2026 | 4:47 PM
TLX - Telix Successfully Prices Upsized US$600M Convertible Bonds
Telix Pharmaceuticals Limited announced the successful pricing and upsizing of its US$600
Telix Pharmaceuticals Limited (TLX)
15 Apr 2026 | 8:14 AM
15 Apr 2026 | 8:14 AM
TLX - Telix Investor Presentation April 2026
Telix Pharmaceuticals Limited's investor presentation in April 2026 outlines significant g
Telix Pharmaceuticals Limited (TLX)
14 Apr 2026 | 5:08 PM
14 Apr 2026 | 5:08 PM
TLX - Telix Refinances Convertible Bonds
Telix Pharmaceuticals Limited announced an offering of US$550 million convertible notes du
Telix Pharmaceuticals Limited (TLX)
14 Apr 2026 | 4:54 PM
14 Apr 2026 | 4:54 PM
Telix Pharmaceuticals Limited (TLX) Recent ASX Announcements
TLX Financial Summary
| Year to Dec | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025F | $122.66 | $34.57 | 61.00% | 82.53 | 0.00 | 0.00% | 0.0% |
| 2024F | $76.18 | $21.47 | 5.70% | 132.88 | 0.00 | 0.00% | 0.0% |
| 2023A | $65.73 | $20.31 | -174.80% | 46.74 | 0.00 | 0.00% | 0.0% |
TLX Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 F | 2025 F | 2023 A | 2024 F | 2025 F | 2023 A | 2024 F | 2025 F | ||
| CSL Limited (CSL) | $53,657M | 0.1108 | -0.1314 | 0.0166 | 12.0141 | 13.8321 | 13.6068 | 3.98% | 3.21% | 3.34% |
| Clinuvel Pharmaceuticals Limited (CUV) | $502M | 0.0287 | 0.0233 | 0.0942 | 13.8579 | 13.5429 | 12.3772 | 0.50% | 0.73% | 1.18% |
| Immutep Limited (IMM) | $77M | 0.1854 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Mesoblast Limited (MSB) | $2,809M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $4,941M | -1.3893 | 0.0000 | -0.1306 | 0.0000 | 271.6418 | 312.4464 | 0.00% | 0.00% | 0.00% |
TLX Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Christian Peter Behrenbruch | Chief Executive Officer, Managing Director | 3 Jan 2017 |
| Ms Jann E Skinner | Non-Executive Director | 19 Jun 2018 |
| Ms Marie Elizabeth McDonald | Non-Executive Director | 3 Mar 2025 |
| Mr David Gill | Non-Executive Director | 11 May 2026 |
| Dr Maria Rivas | Non-Executive Director | 11 May 2026 |
| Mr William (Bill) Jellison | Non-Executive Director | 11 May 2026 |
| Dr Mark Alexander Nelson | Non-Executive Director, Interim Chairman | 17 Sep 2017 |
Telix Pharmaceuticals Limited (TLX) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 11 Jun 2026 | GILL, David | Buy | Direct Shares | 10,200 | $9.434 | $96,221.700 |
| 29 Apr 2026 | BEHRENBRUCH, Christian | Buy | Indirect Shares | 67,935 | $14.671 | $996,699.480 |
| 5 Nov 2025 | BEHRENBRUCH, Christian | Exercise | Options | 100,708 | $4.380 | $441,101.000 |
See all changes in directors' interest & trades for Telix Pharmaceuticals Limited (TLX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
TLX Management
| Name | Position |
|---|---|
| Raphael Ortiz | Chief Executive Officer, Telix International |
| Kevin Richardson | Chief Executive Officer, Telix Precision Medicine |
| Richard Valeix | Chief Executive Officer, Telix Therapeutics |
| Darren Smith | Group Chief Financial Officer |
| David Cade | Group Chief Medical Officer |
| Mary Jessel | Group Chief of Clinical Affairs |
| Darren Patti | Group Chief Operating Officer |
| Lena Moran-Adams | Group General Counsel |
| Shomalin Naidoo | Interim Company Secretary |
| Meredith Crowe | Senior Vice President, People & Culture |
TLX Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Telix Pharmaceuticals Limited (TLX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 28,187,775 (8.30%) | State Street Corporation and subsidiaries |
| 22,419,015 (6.60%) | JPmorgan Chase & Co. and its affiliates |
| 20,675,000 (6.10%) | Elk River Holdings Pty Ltd |
| 20,675,000 (6.10%) | Gnosis Verwaltungsgesellschaft |
TLX Calendar of Events
| Date | Event |
|---|---|
| 19 February 2027 | Report (Annual) |
| 19 February 2027 | Report (Prelim) |
| 20 August 2026 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
